Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
Checkpoint inhibitors were a major breakthrough in the field of oncology. In September 2014, based on the KEYNOTE-001 study, the Food and Drug Administration (FDA) approved pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, for advanced or unresectable melanoma. Up until now, seven P...
Salvato in:
| Autori principali: | , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI AG
2021-03-01
|
| Serie: | Pharmaceuticals |
| Soggetti: | |
| Accesso online: | https://www.mdpi.com/1424-8247/14/4/288 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|